A Phase 3 Randomized Double-blind Study of Adjuvant Immunotherapy with Relatlimab and Nivolumab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma

Brief description of study

The purpose of the study is to compare the effectiveness, safety, and toxicity of two treatments: relatlimab and nivolumab vs nivolumab monotherapy in participants with completely resected Stage III-IV Melanoma. The study drugs relatlimab and nivolumab are investigational, which means that they have not been approved for melanoma by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test these agents in the current trial.

Clinical Study Identifier: s21-01507
ClinicalTrials.gov Identifier: NCT05002569
Principal Investigator: Jeffrey S. Weber.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.